Quan Bui
Cardiovascular Disease · San Diego, CANPI 1831553718
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,856 of the $21,004 with a category attached, or 66.0%. 19 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 40.8% of the total. 2025 is the largest year on record at $12,826, more than ten times the $51 reported in 2020.
Across 104 payments — averaging $201.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$9K
- Bayer$6K
- Baxter Healthcare$2K
- Abiomed$1K
- Abbott$987
- Novo Nordisk$619
- plus $2K from 13 others
Across 4 payments — averaging $24,062 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eidos Therapeutics, Inc.$53K
- Astrazeneca UK Limited$43K
What the payments were for
- Consulting fees$13,85666%
- Travel & lodging$1,2086%
- Food & beverage$5,69627%
- Education$2451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 25 | $8,562 |
| Bayer | 9 | $5,677 |
| Baxter Healthcare | 1 | $2,205 |
| Abiomed | 20 | $1,251 |
| Abbott | 11 | $987 |
| Novo Nordisk | 9 | $619 |
| Kestra Medical Technology Services, Inc. | 4 | $405 |
| Edwards Lifesciences | 3 | $315 |
| Boston Scientific | 2 | $181 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $181 |
| Philips North America LLC | 2 | $177 |
| AstraZeneca | 6 | $131 |
| UCB, Inc. | 1 | $125 |
| Pfizer | 2 | $69 |
| Irhythm Technologies, Inc. | 2 | $41 |
| Lantheus Medical Imaging, Inc. | 2 | $34 |
| Medtronic | 1 | $16 |
| Amgen | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$5,276
- Fluid Systems - Infusion Systems$2,205
- Fluid Systems - Research Devel$2,205
- CAMZYOS$687
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$342
- Assure WCD$312
- Impella$286
- ENSITE PRECISION$245
- CARDIOMEMS$227
- Edwards SAPIEN XT Transcatheter Heart Valve$166
- EMBLEM MRI S-ICD$162
- (3126) ECC Solutions$150
- SAPIEN 3 Ultra RESILIA$128
- Bimzelx$125
How this compares
$21,004 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 16 | $132,383 |
| JardianceEmpagliflozin | 57 | $60,685 |
| EliquisApixaban | 46 | $48,553 |
| EntrestoSacubitril/Valsartan | 42 | $41,491 |
| FarxigaDapagliflozin Propanediol | 29 | $15,928 |
| Repatha SureclickEvolocumab | 24 | $14,595 |
| OzempicSemaglutide | 14 | $12,640 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $3,642 |
| Tacrolimus | 12 | $2,524 |
| Valganciclovir Hcl | 15 | $1,817 |
| Nifedipine ErNifedipine | 26 | $1,564 |
| Metoprolol Succinate | 79 | $1,229 |
| Bumetanide | 37 | $1,199 |
| Potassium Chloride | 16 | $1,114 |
| Rosuvastatin Calcium | 89 | $849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $8,562 | $132,38316 claims |
| PfizerEliquis | $69 | $48,55346 claims |
| AstraZenecaFarxiga | $131 | $15,92829 claims |
| Novo NordiskOzempic | $619 | $12,64014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in San Diego
- Lori DanielsSan Diego$278K
- Michael WilkinsonSan Diego$145K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.